CooperCompanies
Develops contact lenses, fertility services and women’s-health medical devices.
Something off on this page? Send us feedback.
Profile
Develops contact lenses and myopia-management products through CooperVision, while CooperSurgical sells fertility, cryostorage, genomic, contraception and women’s-health devices and services. Contact lenses generate most revenue, with sales distributed across the Americas, Europe, the Middle East, Africa and Asia Pacific.
Operates through two medical-device businesses: CooperVision and CooperSurgical. CooperVision develops and manufactures daily, two-week and monthly contact lenses, including toric, multifocal and myopia-management products. Biofinity, MyDay and MiSight anchor a portfolio designed around broad prescription parameters and recurring replacement demand.
CooperSurgical supplies fertility clinics, OB/GYN offices, hospitals and surgery centers with IVF devices and consumables, donor gametes, cryostorage, genomic testing, contraception, and gynecology and obstetrics devices. Sales span the Americas, Europe, the Middle East, Africa and Asia Pacific, while contact lenses generate most revenue.
Manufacturing scale, practitioner education and a broad fitting range support execution across eye-care channels. Medical-device approvals, quality systems, fertility-treatment activity and sole-sourced materials for some silicone hydrogel lenses and IVF products remain structural dependencies.
Company facts
Categories
Key statistics
Year to date −12.3% · Average volume (30d) 1.8M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Jun 5, 2026 | Needham | Reiterate | Buy | $99 | $86 |
| Jun 5, 2026 | Wells Fargo | Reiterate | Equal Weight | $480 | $66 |
| Jun 4, 2026 | Mizuho Securities | Target | $100 | $85 | |
| Jun 1, 2026 | Piper Sandler | Reiterate | Overweight | $94 | $86 |
| May 27, 2026 | Goldman Sachs | Target | $73 | $61 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jun 4, 2026Q2 FY26 | $1.10 | $1.21 | +10.0% | $1.05B | $1.08B | +2.6% | +8.58% |
| Mar 5, 2026Q1 FY26 | $1.03 | $1.10 | +6.8% | $1.02B | $1.02B | 0.0% | −4.55% |
| Dec 4, 2025Q4 FY25 | $1.11 | $1.15 | +3.6% | $1.06B | $1.07B | +0.4% | +5.67% |
| Aug 27, 2025Q3 FY25 | $1.07 | $1.10 | +2.8% | $1.06B | $1.06B | −0.3% | −12.86% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $964.7M | $1.00B | $1.06B | $1.07B | $1.02B | $1.08B | |
| Gross profit | $660.2M | $679.1M | $692.0M | $601.0M | $695.2M | $735.4M | |
| Operating income | $182.0M | $184.8M | $175.7M | $140.4M | $212.8M | −$31.0M | |
| Net income | $104.3M | $87.7M | $98.3M | $84.6M | $130.8M | −$77.9M | |
| Diluted EPS | $0.52 | $0.44 | $0.49 | $0.43 | $0.66 | −$0.40 | |
| Gross margin | 68.4% | 67.8% | 65.3% | 56.4% | 67.9% | 68.0% | |
| Operating margin | 18.9% | 18.4% | 16.6% | 13.2% | 20.8% | -2.9% |
Fiscal years (4-quarter sums)FY21 $2.92B · FY22 $3.31B · FY23 $3.59B · FY24 $3.90B · FY25 $4.09B
Revenue by product · Q2 FY26
Revenue by geography · Q2 FY26
Balance sheet, Apr 30, 2026Cash & short-term investments $138.8M · Total debt $2.46B · Total assets $12.48B · Shareholders' equity $8.24B
Dividends
Raised for 24 straight years.
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| Jul 26, 2023 | Jul 27 | Aug 11 | $0.03 | |
| Jan 20, 2023 | Jan 23 | Feb 10 | $0.03 | |
| Jul 26, 2022 | Jul 27 | Aug 11 | $0.03 | |
| Jan 20, 2022 | Jan 21 | Feb 9 | $0.03 |
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 195.03M · Float 193.67M · 99.3% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 15.03M | 7.71% | 13F | Aug 7, 2026 |
| Vanguard Capital Management LLC | 12.76M | 6.54% | 13F | Aug 13, 2026 |
| State Street Corp | 8.89M | 4.56% | 13F | Aug 7, 2026 |
| Vanguard Portfolio Management LLC | 8.67M | 4.45% | 13F | Aug 13, 2026 |
| T. Rowe Price Investment Management, Inc. | 7.43M | 3.81% | 13F | Aug 14, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Dec 22, 2025 | Cynthia L. Lucchese | director | +1,784 | $84.06 |
| Dec 18, 2025 | Maria Rivas | director | +1,000 | $82.13 |
| Dec 17, 2025 | Lawrence Erik Kurzius | director | +2,000 | $82.50 |
| Dec 16, 2025 | Albert G. III White | director, officer: President & CEO | +10,000 | $80.80 |
| Dec 16, 2025 | Holly R. Sheffield | officer: President, CSI | +1,230 | $80.75 |
Peers
- Johnson & Johnson
ACUVUE contact lenses and broad surgical devices overlap both segments
- Alcon
DAILIES, TOTAL, and PRECISION brands contest CooperVision lenses
- Bausch + Lomb
Biotrue, ULTRA, and SiHy Daily lens growth overlap contact lenses
- Medtronic
Surgical and gynecology devices overlap CooperSurgical medical devices
- Revvity
ViaCord cord-blood banking overlaps CooperSurgical cryostorage
- Organon
Nexplanon and fertility products overlap Paragard and fertility care
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| CooperCompanies | $71.17 | +0.01% | $13.88B | 60.3 | 15.0 | 3.3 | +7.9% |
| Johnson & Johnson | $268.40 | +0.13% | $645.95B | 31.1 | 22.4 | 6.6 | +6.6% |
| Alcon | $72.15 | +0.21% | $35.12B | 55.4 | 18.6 | 3.3 | +7.5% |
| Bausch + Lomb | $17.15 | 0.00% | $6.13B | — | 17.2 | 1.2 | +9.1% |
| Medtronic | $91.58 | +0.42% | $116.78B | 24.5 | 15.3 | 3.2 | +9.9% |
| Revvity | $127.20 | −1.25% | $14.37B | 61.3 | 22.9 | 4.9 | −1.3% |
| Organon | $13.76 | 0.00% | $3.61B | 17.9 | 3.9 | 0.6 | −2.3% |
| Median | 31.1 | 17.9 | 3.2 | +7.0% |